Curis (CRIS)
(Delayed Data from NSDQ)
$8.84 USD
-0.83 (-8.58%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $8.68 -0.16 (-1.81%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 41 - 60 ( 303 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; Increased Visibility on Aurigene Compounds This Year
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Erivedge Beats and Trials Brewing; Further Focus on ''907 and ''170 To Come
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
More Responses and a Targeted Phase II Group
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Results; Aurigene Programs New Data - Progress; ''''907 ASH Preview
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Results; Aurigene Programs New Data - Progress; ''907 ASH Preview
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Results; Aurigene Programs New Data - Progress; ''907 ASH Preview;
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Aurigene Options Exercised; Upcoming Catalysts; 3Q15 Preview
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q15 Results; Multiple Clinical Milestones in 2H15; Target Tweaked to $5
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Erivedge Subsidy Continues; All Eyes On ''907
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
''907 Makes a Splash as Internal Pipeline Focus Intensifies
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
1Q15 Results: Looking for ''907 to Boost Pipeline Visibility at ASCO
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J